Eiger Biopharmaceuticals is a biotechnology business based in the US. Eiger Biopharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger Biopharmaceuticals employs 56 staff and has a trailing 12-month revenue of around $14.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $1.10 - $14.34 |
|---|---|
| 50-day moving average | $4.59 |
| 200-day moving average | $10.27 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-58.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $14.7 million |
|---|---|
| Gross profit TTM | $11.6 million |
| Return on assets TTM | -52.44% |
| Return on equity TTM | -225.93% |
| Profit margin | 0% |
| Book value | $-1.08 |
| Market Capitalization | $2.6 million |
TTM: trailing 12 months
We're not expecting Eiger Biopharmaceuticals to pay a dividend over the next 12 months.
Eiger Biopharmaceuticals's shares were split on a 1:30 basis on 7 January 2024 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger Biopharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Eiger Biopharmaceuticals shares which in turn could have impacted Eiger Biopharmaceuticals's share price.
Over the last 12 months, Eiger Biopharmaceuticals's shares have ranged in value from as little as $1.1 up to $14.337. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger Biopharmaceuticals's is 1.845. This would suggest that Eiger Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.